190A.T
Chordia Therapeutics Inc.
グロース · 医薬品 · 医薬品 · JP
JPY 72.00
+2.86%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -36.5%
Three-year CAGR
- Revenue
- —
- EBITDA
- +0.6%
- EBIT
- +0.7%
- Net income
- +2.3%
- EPS
- +16.3%
- Free cash flow
- +5.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Feb 1, 2026